Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014-2015

about

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014-2015

Item

http://www.wikidata.org/entity/Q56835140

description

im Jahr 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Susceptibility to ceftobiprole ...... m and Ireland during 2014-2015

@en

Susceptibility to ceftobiprole ...... m and Ireland during 2014-2015

@nl

type

Item

label

Susceptibility to ceftobiprole ...... m and Ireland during 2014-2015

@en

Susceptibility to ceftobiprole ...... m and Ireland during 2014-2015

@nl

prefLabel

Susceptibility to ceftobiprole ...... m and Ireland during 2014-2015

@en

Susceptibility to ceftobiprole ...... m and Ireland during 2014-2015

@nl

P1476

Susceptibility to ceftobiprole ...... m and Ireland during 2014-2015

@en

P2093

Jennifer I Smart

http://www.w3.org/2001/XMLSchema#string

P2860

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci

Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns

Determination of minimum inhibitory concentrations

Hospital-acquired pneumonia: risk factors, microbiology, and treatment.

A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation.

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.

A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia

Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.

Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.

P304

1309-1320

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/IDR.S176369

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kamal Hamed

Anne Santerre Henriksen

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30214251

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

infectious disease

P932

6118268

http://www.w3.org/2001/XMLSchema#string